ArticleCureus2023
A Case Report of Aggressive Post-Infectious Hemophagocytic Lymphohistiocytosis in an Immunocompetent Adult.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an acute inflammatory syndrome triggered by immune events such as infections, inflammation, autoimmune diseases, and malignancies. Initial presentations can range from vague symptoms to infectious features such as fever. Given its aggressive nature, timely diagnosis and immediate treatment are crucial to achieving optimal patient outcomes. Recently, the HLH score (HScore) criteria have been applied as diagnostic criteria, offering a broader scope compared to the previous HLH-2004 score, which was primarily based on pediatric populations. The standard treatment for decades has involved the combination of etoposide and high-dose steroids, and it is recommended to initiate treatment as soon as possible, even in the absence of a bone marrow test or when there is suspicion of the diagnosis. In this case presentation, we aim to underscore the significance of maintaining a high level of suspicion for HLH and the importance of promptly initiating treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.